Abstract Details

Title Medical Cannabis in the Treatment of Non-motor and Motor Symptoms in Parkinson’s Disease: A Systematic Review and Meta-analysis

Topic Movement Disorders

Presentation(s) P6 - Poster Session 6 (5:00 PM-6:00 PM)

Poster/Presentation
Number 17-013

Objective

To evaluate the efficacy and safety of medical cannabis for non-motor or motor symptoms of Parkinson’s disease.

Background Parkinson’s disease (PD) is associated with progressively impairing symptoms that lead to disability and to a decline in patients' quality of life and independence in daily activities.

Design/Methods We searched PubMed, Embase, and Web of Science for studies comparing extracts of cannabidiol (CBD) or tetrahydrocannabinol (THC) with placebo. The outcomes evaluated included overall assessments of PD (PDQ-39 and total UPDRS scores) as well as specific assessments of both non-motor symptoms (pain, cognition, sleep, anxiety and depression) and motor symptoms (UPDRS-III). Statistical analyses were performed using RStudio 2024.12.0+467. Heterogeneity was assessed using I², and pooled estimates were calculated using a random-effects model.

Results We included 719 patients from 10 randomized controlled trials. CBD and THC extracts were administered as either oil or capsule to 455 patients, with a mean age of 63 years, of whom 55.16% were male. Our study showed no show statistically significant difference between groups for overall PD burden – PDQ-39 (MD=0.71 [-1.84;3.27]; p=0.58) and total UPDRS (MD=1.42 [-1.43;4.27]; p=0.33). Furthermore, treatment with cannabis did not improve pain (SMD=0.01 [-0.23;0.25]; p=0.96), cognition (MD=0.57 [-0.24;1.39]; p=0.17), sleep (SMD=0.11 [-0.17;0.40]; p=0.44), and depression (SMD=0.09 [-0.19;0.37]; p=0.54); while placebo showed a significantly greater effect than cannabis for anxiety (SMD=0.26 [0.03;0.49]; p=0.024). Additionally, there was no significant difference between groups for motor outcome – UPDRS-III (MD=-1.24 [-3.91;1.43] p=0.36).

Conclusions These findings suggest that the use of medical cannabis was not associated with statistically significant benefits for motor or non-motor symptoms in patients with Parkinson’s disease.

Authors/Disclosures
Giovanna Salema Pascual PRESENTER	Miss Salema Pascual has nothing to disclose.
Leonardo Pipek, MD (University of São Paulo)	Dr. Pipek has nothing to disclose.
Pedro Henrique Reginato	Mr. Reginato has nothing to disclose.
Jacy B. Parmera, MD, PhD	Dr. Parmera has nothing to disclose.

��ɫ��

��ɫ��